Biocryst pharmaceuticals, inc. BCRX.US Overview
BCRX AI Analysis & Strategy
Browsing restrictions can be lifted for a fee.
BCRX Current Performance
-2.06%
Biocryst pharmaceuticals, inc.
-2.38%
Avg of Sector
-0.30%
S&P500
BCRX Key Information
BCRX Revenue by Segments
Browsing restrictions can be lifted for a fee.
BCRX Net Income
Browsing restrictions can be lifted for a fee.
BCRX Cash Flow
Browsing restrictions can be lifted for a fee.
BCRX Profit Margin
Browsing restrictions can be lifted for a fee.
BCRX PE Ratio River
Browsing restrictions can be lifted for a fee.
BCRX Financial Forecast
Browsing restrictions can be lifted for a fee.
| Quarterly | EPS Forecast | QoQ | Max | Min |
|---|---|---|---|---|
| 2025Q1 | ||||
| 2025Q2 | ||||
| 2025Q3 | ||||
| 2025Q4 | ||||
| 2026Q1 |
BCRX Earnings Table
Unit : USD
| QTR | Non-GAAP EPS | EPS YoY | EPS Surprise % | Sales | Sales YoY | Sales Surprise % | NPM |
|---|---|---|---|---|---|---|---|
| Current | |||||||
| 2024Q4 | |||||||
| 2024Q3 | |||||||
| 2024Q2 | |||||||
| 2024Q1 |
BCRX Profile
BioCryst Pharmaceuticals, Inc., a biotechnology company, discovers novel, oral, and small-molecule medicines. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema. It is also developing BCX9930, an oral factor D inhibitor, which is in Phase II clinical trial for complement-mediated diseases; BCX9250, an oral activin receptor-like kinase-2 inhibitor that is in Phase I clinical trial to treat fibrodysplasia ossificans progressiva; and Galidesivir, a RNA dependent-RNA polymerase inhibitor, which is in Phase I clinical trial to treat various RNA viruses, including Marburg, Yellow Fever, Ebola, and Zika. The company has collaborations and in-license relationships with the Torii Pharmaceutical Co., Ltd.; Seqirus UK Limited; Shionogi & Co., Ltd.; Green Cross Corporation; Mundipharma International Holdings Limited; National Institute of Allergy and Infectious Diseases; Biomedical Advanced Research and Development Authority; the U.S. Department of Health and Human Services; and The University of Alabama at Birmingham, as well as Albert Einstein College of Medicine of Yeshiva University and Industrial Research, Ltd. BioCryst Pharmaceuticals, Inc. was founded in 1986 and is headquartered in Durham, North Carolina.
Price of BCRX
BCRX FAQ
When is BCRX's latest earnings report released?
The most recent financial report for Biocryst pharmaceuticals, inc. (BCRX) covers the period of 2025Q1 and was published on 2025/03/31. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating BCRX's short-term business performance and financial health. For the latest updates on BCRX's earnings releases, visit this page regularly.
What is the operating profit of BCRX?
According to the latest financial report, Biocryst pharmaceuticals, inc. (BCRX) reported an Operating Profit of 21.23M with an Operating Margin of 14.59% this period, representing a growth of 246.51% compared to the same period last year. Operating Profit reflects the company's core business efficiency and cost control, making it a key indicator for evaluating operational strength and profitability.
How is BCRX's revenue growth?
In the latest financial report, Biocryst pharmaceuticals, inc. (BCRX) announced revenue of 145.53M, with a Year-Over-Year growth rate of 56.89%. Revenue growth can be driven by product mix changes, market share expansion, price adjustments, or international market penetration. Investors should also monitor gross margin and regional revenue distribution for a comprehensive view of growth quality and sustainability.
How much debt does BCRX have?
As of the end of the reporting period, Biocryst pharmaceuticals, inc. (BCRX) had total debt of 829.29M, with a debt ratio of 1.73. Long-term debt comprises a higher/lower proportion. The level of financial leverage directly impacts the company's capital structure and interest coverage. If debt is high, pay attention to interest expenses and refinancing risks. Conversely, a low-leverage structure indicates greater risk tolerance but potentially less growth flexibility.
How much cash does BCRX have?
At the end of the period, Biocryst pharmaceuticals, inc. (BCRX) held Total Cash and Cash Equivalents of 105.48M, accounting for 0.22 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.
Does BCRX go with three margins increasing?
In the latest report, Biocryst pharmaceuticals, inc. (BCRX) did not achieve the “three margins increasing” benchmark, with a gross margin of 96.9%%, operating margin of 14.59%%, and net margin of 0%%. This demonstrates limited improvement in profitability, which is a key signal for fundamental analysis. Investors should consider margin trends alongside other financial indicators to assess BCRX's profit trajectory and future growth potential.
Is BCRX's EPS continuing to grow?
According to the past four quarterly reports, Biocryst pharmaceuticals, inc. (BCRX)'s earnings per share (EPS) shows a steady growth trend, with the latest EPS at 0. If EPS continues to rise due to revenue growth and cost optimization, it can support P/E valuation recovery and attract long-term investors.
What is the FCF of BCRX?
Biocryst pharmaceuticals, inc. (BCRX)'s Free Cash Flow (FCF) for the period is -27.66M, calculated as Operating Cash Flow minus Capital Expenditures, representing a rise of 48.7% compared with the previous period. Positive FCF growth provides stable funding for dividends, debt repayment, or strategic acquisitions, and is an important measure of true profitability and shareholder return potential.
What are the PEG ratio and PE ratio of BCRX?
The latest valuation data shows Biocryst pharmaceuticals, inc. (BCRX) has a Price-To-Earnings (PE) ratio of -40.19 and a Price/Earnings-To-Growth (PEG) ratio of -122.2. A PEG below 1 usually suggests the market is underestimating growth potential, while a PEG above 1 indicates high growth expectations are already priced in. Investors should conduct a comprehensive valuation by considering historical growth, market forecasts, and industry cycles.